ANI Pharmaceuticals, Inc. announced preliminary unaudited financial results for Q2 2025 on July 23, expecting net revenues of $22.3 million from ILUVIEN® and YUTIQ®. The results are not finalized, so investors should be cautious with this preliminary data.